打开APP

12亿美元!罗氏入股Foundation Medicine开发个性化癌症疗法

  1. Foundation Medicine
  2. 个体化疗法
  3. 分子诊断
  4. 罗氏
  5. 肿瘤

来源:生物谷 2015-01-13 09:34

制药巨头罗氏公司最近宣布,公司已经与分子诊断公司Foundation Medicine公司达成合作意向,罗氏公司将入股Foundation Medicine公司,作为主要股东之一参与公司的日常管理。

2015年1月13日讯 /生物谷BIOON/ --制药巨头罗氏公司最近宣布,公司已经与分子诊断公司Foundation Medicine公司达成合作意向,罗氏公司将入股Foundation Medicine公司,作为主要股东之一参与公司的日常管理。

协议约定,罗氏公司将以每股50美元的价格向Foundation Medicine公司支付7亿8千万美元,这一价格也比上周五公司的股价高出了近一倍之多。同时,公司还以相同的价格再额外购买了价值2亿5千万美元的股票。这些投资再加上罗氏公司与Foundation Medicine公司之前价值1亿5千万美元的投资,使得罗氏公司获得了其56%的股份,成为了Foundation Medicine公司名副其实的大东家。

罗氏公司通过此次协议入股Foundation Medicine公司的最大目的,是希望借助其先进的测序技术为公司未来开发肿瘤个性化治疗扫平道路。Foundation Medicine公司自从成立以来就致力于开发肿瘤的基因检测技术,而众所周知,如果能够医生能够在癌症早期就检测出肿瘤发生,那么对及早治疗肿瘤有着难以估量的作用。

而作为生物医药领域最为财大气粗的土豪之一,罗氏公司此次的做法出乎一些人的意料。2014年以来,生物医药市场掀起了一场十年难得一见的收购狂潮,罗氏公司此次并没有选择收购兼并这种"简单粗暴"的方法,而是采取入股投资的形式的确是有些另类。

另一方面,Foundation Medicine公司也对此次的协议表示满意,公司高层认为此次罗氏的注资,将加速公司在分子诊断领域的发展。今后双方将在肿瘤的DNA检测技术领域建立起更加密切的合作。(生物谷Bioon.com)

详细英文报道:

Roche ($RHHBY) is throwing the full weight of its global rep and more than a billion dollars behind Foundation Medicine's ($FMI) ambitious sequencing technology for guiding the personalized treatment of cancer as well as the development of new oncology meds. The pharma giant has wrapped a deal to buy up a majority stake in the molecular diagnostics company for $780 million at $50 a share--a premium rate that's more than twice Friday's close of $23.93.

In addition to gaining control of the Cambridge, MA-based biotech, Roche is injecting another $250 million into the company--buying new shares, also at $50 a share--while reserving a further $150 million-plus for a collaboration on drug combinations, clinical trials and next-gen companion diagnostics. Roche will be left with around 56% of the company's stock.

Foundation's main claim to fame today is its FoundationOne product, which sequences cancer samples in order to come up with a full genomic profile that can be used to guide treatment as well as match patients to clinical studies of new cancer therapies. And Roche, which has staked out a big place for itself in companion diagnostics and new cancer meds, clearly thinks that Foundation's business can lend a big assist in realizing its plans in the rapidly changing oncology field.

Daniel O'Day, the COO of Roche's pharma division and former chief of diagnostics, is joining the Foundation board in this deal.

In the past, Roche has travelled a sometimes rocky road as it bagged new tech outfits and tried to assimilate the developing science into their operations. But this time, the pharma giant is taking a different path, not unlike the one it has followed with some close development partners like Chugai and earlier with Genentech, before coming back for the whole thing. Rather than buying the company, which it probably could have done for a smaller premium than the one revealed today, it's leaving Foundation CEO Michael Pellini and his crew as independent operators, free to continue their work under Roche's wing. Foundation can keep its entrepreneurial roots intact, and Roche stands to benefit from their future evolution.

The deal with Roche, says Pellini, "accelerates the business we have been building over the course of the past 4 or 5 years": taking a molecular approach to changing the way cancer is treated. Specifically, he adds, it allows Foundation-which now has about 300 staffers with plans to keep growing-to collaborate with Roche on circulating tumor DNA geared to monitoring disease and taking a diagnostic approach to immunotherapeutics, a central focus at Roche's R&D groups.

O'Day, for his part, says that taking a majority stake in the company was the best way to ensure that Roche got what it was looking for: An innovative partner who would make all things Roche a top priority at the company.

"You need significant ownership to make sure there's unfettered collaboration and it can go broad and deep," says O'Day. "This is not a business that is core to Roche today. This is a molecular information business, not diagnostic."

Roche has long been intrigued by Foundation Medicine. A little more than two years ago Roche's venture arm came in on a round to back the fledgling FMI and its work on a commercial diagnostic test that could be used to match cancer drugs with patients--billing it as a key tool for drug development companies.

Foundation Medicine attracted plenty of positive attention for its diagnostics test work in oncology. The company was named a Fierce 15 biotech in 2012, the day before Roche joined Google ($GOOG), Third Rock and others as a key backer. And Foundation then went public soon after the biotech IPO window opened wide in 2013. The company closed Friday with a share price of $23.93 and a market cap of $677 million.

The deal for the company is all but done. Three shareholders--Third Rock Ventures, Kleiner Perkins Caufield & Byers and Google Ventures, which control 31% of the company--have already committed to vote for it. And the news marks the busy beginning of deals week in San Francisco, as the industry gathers to review the year ahead in biotech at the annual JP Morgan event.

This is the time when industry players like to flex their financial muscles to demonstrate some heavy lifting capabilities. And Roche is clearly willing to play in the heavyweight category.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->